Sign in or create an account to add this stock to your watchlist.
About Adamis Pharmaceuticals (NASDAQ:ADMP)
Adamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, develops and commercializes products in the therapeutic areas of allergy and respiratory disease in the United States. The company's specialty pharmaceutical product candidates comprise Symjepi (epinephrine) Injection pre-filled syringe (PFS) for use in the emergency treatment of acute allergic reactions, including anaphylaxis. It also offers dry powder inhaler products consisting of albuterol (APC-2000) for the treatment of bronchospasms; fluticasone (APC-4000) for the treatment of asthma; beclomethasone (APC-1000), a metered dose inhaler product for the asthma; and naloxone injection product candidates (APC-6000) for the treatment of opioid overdose. In addition, the company provides corticosteroids, hormone replacement therapies, hospital outsourcing products, injectables, urological preparations, ophthalmic preparations, topical compounds for pain, and men's and women's health products; and certain veterinary pharmaceutical products for animals. Adamis Pharmaceuticals Corporation is headquartered in San Diego, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:ADMP
CUSIPN/A
Phone858-997-2400
Debt
Debt-to-Equity Ratio0.07
Current Ratio1.88
Quick Ratio1.57
Price-To-Earnings
Trailing P/E Ratio-4.83
Forward P/E Ratio-5.88
P/E GrowthN/A
Sales & Book Value
Annual Sales$13.07 million
Price / Sales11.11
Cash FlowN/A
Price / CashN/A
Book Value$1.18 per share
Price / Book3.69
Profitability
EPS (Most Recent Fiscal Year)($0.90)
Net Income$-25,530,000.00
Net Margins-207.24%
Return on Equity-71.68%
Return on Assets-56.06%
Miscellaneous
Employees126
Outstanding Shares33,390,000
Adamis Pharmaceuticals (NASDAQ:ADMP) Frequently Asked Questions
What is Adamis Pharmaceuticals' stock symbol?
Adamis Pharmaceuticals trades on the NASDAQ under the ticker symbol "ADMP."
How were Adamis Pharmaceuticals' earnings last quarter?
Adamis Pharmaceuticals Co. (NASDAQ:ADMP) released its earnings results on Thursday, May, 10th. The specialty pharmaceutical company reported ($0.23) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.17) by $0.06. The specialty pharmaceutical company earned $3.18 million during the quarter, compared to analysts' expectations of $3.34 million. Adamis Pharmaceuticals had a negative return on equity of 71.68% and a negative net margin of 207.24%. View Adamis Pharmaceuticals' Earnings History.
When is Adamis Pharmaceuticals' next earnings date?
What price target have analysts set for ADMP?
4 Wall Street analysts have issued 1-year price objectives for Adamis Pharmaceuticals' shares. Their forecasts range from $7.00 to $10.00. On average, they expect Adamis Pharmaceuticals' share price to reach $7.8750 in the next year. View Analyst Ratings for Adamis Pharmaceuticals.
What are Wall Street analysts saying about Adamis Pharmaceuticals stock?
Here are some recent quotes from research analysts about Adamis Pharmaceuticals stock:
- 1. Maxim Group analysts commented, "Adamis reported 1Q18 with revenue of $3.2M from the compounding business, up 11.9% sequentially. The company ended the period with a net loss of $7.6M and $10.1M in cash on the balance sheet. Growing revenue in the compounding business should continue to partially offset cash burn and we expect that a partnership for Symjepi to come with an upfront payment that could extend the runway. Partnering discussions are advancing. We have removed the risk cut in our Symjepi model (prior 30%) and made some other minor model, increasing PT to $10, from $5.." (5/11/2018)
- 2. According to Zacks Investment Research, "Adamis Pharmaceuticals Corporation, formerly Cellegy Pharmaceuticals, Inc., is a specialty pharmaceutical company engaged engages in the research, development, and commercialization of prescription medicines for the treatment of viral infections. Adamis Pharmaceuticals is composed of two wholly owned subsidiaries, Adamis Labs and Adamis Viral Therapies. Adamis Labs is a commercial stage specialty pharmaceutical company targeting high-prescribing physicians in the allergy, respiratory and pediatric medicine market segments. To complement and add to the sales efforts of Adamis Labs, Adamis Viral Therapies is focused on the development of patented, highly-valued proprietary vaccine technology that Adamis believes has the potential to prevent or treat infections such as influenza or chronic hepatitis. Adamis also provides packaging for pharmaceutical and nutraceutical products. The company is headquartered in Del Mar, California. " (3/16/2018)
Who are some of Adamis Pharmaceuticals' key competitors?
Some companies that are related to Adamis Pharmaceuticals include Keryx Biopharmaceuticals (KERX), Aduro BioTech (ADRO), Aclaris Therapeutics (ACRS), BeyondSpring (BYSI), Lannett (LCI), Geron (GERN), Prothena (PRTA), Akebia Therapeutics (AKBA), ChemoCentryx (CCXI), AC Immune (ACIU), CannTrust (CNTTF), StemlineTherapeutics (STML), Clementia Pharmaceuticals (CMTA), Kura Oncology (KURA) and Achaogen (AKAO).
Who are Adamis Pharmaceuticals' key executives?
Adamis Pharmaceuticals' management team includes the folowing people:
- Mr. Richard C. Williams, Chairman and Consultant (Age 74)
- Dr. Dennis J. Carlo Ph.D., Chief Exec. Officer, Pres and Director (Age 75)
- Mr. Robert O. Hopkins, Chief Financial Officer, VP of Fin. and Sec. (Age 58)
- Mr. David J. Marguglio, Chief Bus. Officer, Sr. VP and Director (Age 48)
- Mr. Robert B. Rothermel, Consultant and Director (Age 74)
Has Adamis Pharmaceuticals been receiving favorable news coverage?
Media coverage about ADMP stock has trended somewhat positive on Monday, Accern Sentiment Analysis reports. The research firm scores the sentiment of media coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Adamis Pharmaceuticals earned a coverage optimism score of 0.11 on Accern's scale. They also assigned news articles about the specialty pharmaceutical company an impact score of 46.76 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company's share price in the next several days.
Who are Adamis Pharmaceuticals' major shareholders?
Which major investors are buying Adamis Pharmaceuticals stock?
How do I buy shares of Adamis Pharmaceuticals?
Shares of ADMP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Adamis Pharmaceuticals' stock price today?
One share of ADMP stock can currently be purchased for approximately $4.35.
How big of a company is Adamis Pharmaceuticals?
Adamis Pharmaceuticals has a market capitalization of $156.93 million and generates $13.07 million in revenue each year. The specialty pharmaceutical company earns $-25,530,000.00 in net income (profit) each year or ($0.90) on an earnings per share basis. Adamis Pharmaceuticals employs 126 workers across the globe.
How can I contact Adamis Pharmaceuticals?
Adamis Pharmaceuticals' mailing address is 11682 EL CAMINO REAL SUITE 300, SAN DIEGO CA, 92130. The specialty pharmaceutical company can be reached via phone at 858-997-2400 or via email at [email protected]
MarketBeat Community Rating for Adamis Pharmaceuticals (ADMP)
MarketBeat's community ratings are surveys of what our community members think about Adamis Pharmaceuticals and other stocks. Vote "Outperform" if you believe ADMP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ADMP will underperform the S&P 500 over the long term. You may vote once every thirty days.
Adamis Pharmaceuticals (NASDAQ:ADMP) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
4 Wall Street analysts have issued ratings and price targets for Adamis Pharmaceuticals in the last 12 months. Their average twelve-month price target is $7.8750, suggesting that the stock has a possible upside of 81.03%. The high price target for ADMP is $10.00 and the low price target for ADMP is $7.00. There are currently 4 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 3.00 | 3.00 | 3.00 | 3.00 |
| Ratings Breakdown: | 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $7.8750 | $6.50 | $7.3333 | $10.00 |
| Price Target Upside: | 81.03% upside | 85.71% upside | 103.70% upside | 115.05% upside |
Adamis Pharmaceuticals (NASDAQ:ADMP) Consensus Price Target History
Adamis Pharmaceuticals (NASDAQ:ADMP) Analyst Ratings History
Show:
(Data available from 5/21/2016 forward)
Adamis Pharmaceuticals (NASDAQ:ADMP) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Adamis Pharmaceuticals (NASDAQ ADMP) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 12.20%
Institutional Ownership Percentage: 10.47%
Adamis Pharmaceuticals (NASDAQ ADMP) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 6/2/2016 | David J Marguglio | VP | Sell | 700 | $9.00 | $6,300.00 | 101,527 |  |
| 5/16/2016 | David J Marguglio | SVP | Sell | 4,000 | $8.08 | $32,320.00 | 102,227 | |
| 5/9/2016 | David J Marguglio | SVP | Sell | 4,860 | $10.00 | $48,600.00 | 106,227 | |
| 5/4/2016 | David J Marguglio | SVP | Sell | 4,860 | $9.17 | $44,566.20 | 112,227 | |
| 5/3/2016 | David J Marguglio | SVP | Sell | 1,140 | $9.00 | $10,260.00 | 117,087 | |
| 4/14/2016 | David J Marguglio | SVP | Sell | 12,000 | $7.52 | $90,240.00 | 118,227 | |
| 8/14/2015 | Robert B Rothermel | Director | Buy | 7,000 | $3.33 | $23,310.00 | | |
| 4/20/2015 | David J Marguglio | SVP | Sell | 200 | $5.00 | $1,000.00 | | |
| 4/14/2015 | David J Marguglio | SVP | Sell | 2,200 | $5.01 | $11,022.00 | | |
| 3/4/2015 | David J Marguglio | SVP | Sell | 11,800 | $7.09 | $83,662.00 | | |
| 3/2/2015 | David J Marguglio | SVP | Sell | 7,000 | $6.45 | $45,150.00 | | |
| 2/13/2015 | Ahmed Shayan Fazlur Rahman | Major Shareholder | Sell | 12,076 | $6.41 | $77,407.16 | | |
| 2/12/2015 | Ahmed Shayan Fazlur Rahman | Major Shareholder | Sell | 38,000 | $6.40 | $243,200.00 | | |
| 2/3/2015 | Ahmed Shayan Fazlur Rahman | Major Shareholder | Sell | 30,000 | $6.75 | $202,500.00 | | |
| 1/5/2015 | David J Marguglio | VP | Sell | 7,000 | $6.18 | $43,260.00 | | |
| 12/30/2014 | David J Marguglio | SVP | Sell | 12,228 | $6.09 | $74,468.52 | | |
| 12/29/2014 | David J Marguglio | VP | Sell | 772 | $6.00 | $4,632.00 | | |
| 12/12/2014 | David J Marguglio | SVP | Sell | 4,000 | $5.18 | $20,720.00 | | |
| 9/2/2014 | William C Denby | Director | Buy | 2,500 | $5.06 | $12,650.00 | | |
| 8/29/2014 | Robert B Rothermel | Director | Buy | 5,500 | $4.03 | $22,165.00 | | |
| 6/2/2014 | David J Marguglio | SVP | Sell | 4,000 | $5.56 | $22,240.00 | | |
| 8/14/2013 | Ahmed Shayan Fazlur Rahman | Major Shareholder | Sell | 7,015 | $0.57 | $3,998.55 | | |
| 8/7/2013 | Ahmed Shayan Fazlur Rahman | Major Shareholder | Sell | 40,000 | $0.56 | $22,400.00 | | |
| 8/2/2013 | Ahmed Shayan Fazlur Rahman | Major Shareholder | Sell | 67,960 | $0.57 | $38,737.20 | | |
| 7/30/2013 | Ahmed Shayan Fazlur Rahman | Major Shareholder | Sell | 10,328 | $0.56 | $5,783.68 | | |
| 7/26/2013 | Ahmed Shayan Fazlur Rahman | Major Shareholder | Sell | 95,000 | $0.56 | $53,200.00 | | |
| 7/23/2013 | Ahmed Shayan Fazlur Rahman | Major Shareholder | Sell | 141,224 | $0.57 | $80,497.68 | | |
(Data available from 1/1/2013 forward)
Adamis Pharmaceuticals (NASDAQ ADMP) News Headlines
| Source: |
|
Adamis Pharmaceuticals (NASDAQ:ADMP) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Adamis Pharmaceuticals (NASDAQ:ADMP) Income Statement, Balance Sheet and Cash Flow Statement
Adamis Pharmaceuticals (NASDAQ ADMP) Stock Chart for Monday, May, 21, 2018
Loading chart…
